Confusing Extracted from Simply Wall Street
MBX (CA$0.84) is trading below our estimate
of fair value (CA$1.22)
MBX's earnings (32.1% per year) are forecast to grow faster than the Canadian market (11.6% per year).
MBX's revenue (18.4% per year) is forecast to grow faster than the Canadian market (5.6% per year).
MBX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
And yet they downgrade because of one analyst that is relativley new to the game.
I would sure like to hear from some others